Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade on Streptozotocin-Induced Diabetic Nephropathy

Basit Öğe Kaydı
dc.contributor.authorSaniye, Sen
dc.contributor.authorMehmet, Kanter
dc.contributor.authorSedat, Ustundag
dc.contributor.authorCevat, Aktas
dc.contributor.authorDogutan, Haluk
dc.contributor.authorOmer, Yalcin
dc.date.accessioned2024-06-12T11:13:20Z
dc.date.available2024-06-12T11:13:20Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this study was designed to investigate the possible beneficial effects of the angiotensin-converting enzyme (ACE) inhibitor, Quinapril (Q) and, the angiotensin (ang) II T1 (AT1) receptor blocker, irbesartan (Irb), in streptozotocin (STZ)-induced diabetes in rats. The rats were randomly allotted into one of five experimental groups: A (control), B (diabetic untreated), C (diabetic treated with Q), D (diabetic treated with Irb), and E (diabetic treated with QIrb), each group containing 10 animals. Groups B-E received STZ. Diabetes was induced in four groups by a single intraperitoneal (i.p) injection of STZ (50 mg/kg, freshly dissolved in 5 mmol/L citrate buffer, pH 4.5). Two days after STZ treatment, development of diabetes in four experimental groups was confirmed by measuring blood glucose levels in a tail vein blood samples. Rats with blood glucose levels of 250 mg/dL or higher were considered to be diabetic. The rats in Q-, Irb-, and QIrb-treated groups were given Q (in a dose of 3 mg/kg body weight), Irb (5 mg/kg body weight), and QIrb (in a dose of 1.5 mg/kg + 2.5 mg/kg body weight) once a day orally by using intra-gastric intubation for 12 weeks starting two days after STZ injection. Treatment of Q and especially Irb reduced the glomerular size and thickening of capsular, glomerular, and tubular basement membranes; and increased amounts of mesangial matrix and tubular dilatation and renal function as compared with diabetics untreated. Notably, the better effects were obtained when Q and Irb given together. We conclude that Q, Irb, and especially Q+Irb therapy causes renal morphologic and functional improvement after STZ-induced diabetes in rats. We believe that further preclinical research into the utility of Q and Irb treatment, alone or its combination, may indicate its usefulness as a potential treatment in diabetic nephropathy (DNp).en_US
dc.identifier.doi10.1080/08860220802495248
dc.identifier.endpage1033en_US
dc.identifier.issn0886-022X
dc.identifier.issn1525-6049
dc.identifier.issue10en_US
dc.identifier.pmid19016156en_US
dc.identifier.scopus2-s2.0-57049112199en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1023en_US
dc.identifier.urihttps://doi.org/10.1080/08860220802495248
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23501
dc.identifier.volume30en_US
dc.identifier.wosWOS:000261019100013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofRenal Failureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectQuinaprilen_US
dc.subjectIrbesartanen_US
dc.subjectTGF-1en_US
dc.subjectUltrastructureen_US
dc.subjectRenal Functionen_US
dc.subjectDiabetic Nephropathyen_US
dc.subjectRandomized Controlled-Trialen_US
dc.subjectGrowth-Factor-Betaen_US
dc.subjectAce-Inhibitionen_US
dc.subjectAt(2) Receptoren_US
dc.subjectHypertensionen_US
dc.subjectExpressionen_US
dc.subjectMicroalbuminuriaen_US
dc.subjectMechanismen_US
dc.subjectDiseaseen_US
dc.subjectSystemen_US
dc.titleEffect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Blockade on Streptozotocin-Induced Diabetic Nephropathyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu